With IPO, have the capital and resources for clinical studies: Bicara CEO

Claire Mazumdar, chief executive of Boston-based Bicara Therapeutics, said the company has sufficient funds and resources to carry out clinical studies after its recent $315 million initial public offering (IPO). Claire is the niece of Biocon chief Kiran Mazumdar Shaw.